汇宇制药：拟出资1.5亿元参设私募基金

Core Viewpoint - The company aims to enhance its investment strategies and resource integration by establishing a private equity fund focused on the biomedical sector, particularly targeting late-stage clinical projects with clear commercial potential [1] Group 1: Investment Strategy - The company plans to collaborate with Hangzhou Xiaochi Private Equity Fund Management Co., Ltd. and Chengdu Guanghua Wutong Equity Investment Fund Management Co., Ltd. to set up a private equity fund named Chengdu Huiyu Xiaochi Biomedical Venture Capital Partnership (Limited Partnership) [1] - The initial subscription scale of the private equity fund is set at RMB 400 million, with the company committing RMB 150 million, representing 37.50% of the total initial subscription amount [1] Group 2: Focus Areas - The fund will primarily invest in the biomedical field, concentrating on projects that are in the critical late-stage clinical phase and possess clear commercial viability [1] Group 3: Current Status - The private equity fund is currently in the planning stage, with the partnership agreement not yet formally signed and the business registration not completed [1] - The company will proceed with the establishment, filing, and subsequent funding of the fund in accordance with relevant laws and regulations [1]